- Home
- QLGN vs NBY Comparison
QLGN vs NBY Comparison
Compare QLGN & NBY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- QLGN
- NBY
- Stock Information
- Founded
- QLGN 1996
- NBY 2000
- Country
- QLGN United States
- NBY United States
- Employees
- QLGN N/A
- NBY N/A
- Industry
- QLGN Biotechnology: Pharmaceutical Preparations
- NBY
- Sector
- QLGN Health Care
- NBY
- Exchange
- QLGN Nasdaq
- NBY Nasdaq
- Market Cap
- QLGN 2.4M
- NBY 2.8M
- IPO Year
- QLGN N/A
- NBY 2007
- Fundamental
- Price
- QLGN $3.55
- NBY $0.63
- Analyst Decision
- QLGN
- NBY Strong Buy
- Analyst Count
- QLGN 0
- NBY 1
- Target Price
- QLGN N/A
- NBY $0.85
- AVG Volume (30 Days)
- QLGN 110.9K
- NBY 107.9K
- Earning Date
- QLGN 04-07-2025
- NBY 03-25-2025
- Dividend Yield
- QLGN N/A
- NBY N/A
- EPS Growth
- QLGN N/A
- NBY N/A
- EPS
- QLGN N/A
- NBY N/A
- Revenue
- QLGN N/A
- NBY $13,844,000.00
- Revenue This Year
- QLGN N/A
- NBY N/A
- Revenue Next Year
- QLGN N/A
- NBY $11.73
- P/E Ratio
- QLGN N/A
- NBY N/A
- Revenue Growth
- QLGN N/A
- NBY 15.40
- 52 Week Low
- QLGN $2.96
- NBY $0.07
- 52 Week High
- QLGN $29.45
- NBY $6.30
- Technical
- Relative Strength Index (RSI)
- QLGN 47.06
- NBY 44.89
- Support Level
- QLGN $3.16
- NBY $0.61
- Resistance Level
- QLGN $3.75
- NBY $0.71
- Average True Range (ATR)
- QLGN 0.21
- NBY 0.05
- MACD
- QLGN 0.06
- NBY -0.01
- Stochastic Oscillator
- QLGN 67.25
- NBY 27.27
About QLGN Qualigen Therapeutics Inc.
Qualigen Therapeutics Inc is a early-clinical-stage therapeutics company focused on developing treatments for adult and pediatric cancer. The company's business consists of one early-clinical-stage therapeutic program (QN-302) and one preclinical therapeutic program. The company's lead program, QN-302, is an investigational small molecule G-quadruplexes (G4)-selective transcription inhibitor with strong binding affinity to G4s prevalent in cancer cells.
About NBY NovaBay Pharmaceuticals Inc.
NovaBay Pharmaceuticals Inc is a biopharmaceutical company that develops and sells scientifically-created and clinically eyecare and skincare products. Its product, Avenova Antimicrobial Lid and Lash Solution (Avenova Spray), is laboratory tested to have broad antimicrobial properties as it removes foreign material including microorganisms and debris from the skin around the eye, including the eyelid. Avenova Spray is available directly to consumers through online distribution channels and is also often prescribed and dispensed by eyecare professionals for blepharitis and dry-eye disease. It has two reportable segments: Eyecare and Wound Care and Skincare.